42 results on '"Kaiser, Ulrich"'
Search Results
2. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)
3. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia
4. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma
5. Creating marketing innovation abroad: The value of marketing professionals in foreign MNC subsidiaries
6. Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
7. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
8. Spin doctors vs the spawn of capitalism: Who founds university and corporate startups?
9. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
10. Befragung von Hausärzt*innen zur Versorgung von Patienten unter oralen Tyrosinkinaseinhibitoren
11. The value of publicly available, textual and non-textual information for startup performance prediction
12. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial
13. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
14. Does the mobility of R&D labor increase innovation?
15. Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark
16. Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome
17. Long-run effects of public–private research joint ventures: The case of the Danish Innovation Consortia support scheme
18. Is self-employment really a bad experience?: The effects of previous self-employment on subsequent wage-employment wages
19. Do media consumers really dislike advertising? An empirical assessment of the role of advertising in print media markets
20. Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Systemic Mastocytosis
21. Price structure in two-sided markets: Evidence from the magazine industry
22. Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)
23. An empirical test of models explaining research expenditures and research cooperation: evidence for the German service sector
24. Measuring knowledge spillovers in manufacturing and services: an empirical assessment of alternative approaches
25. Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience
26. Worker-level and firm-level effects of a wage subsidy program for highly educated labor: Evidence from Denmark
27. Chapter 9 - Newspapers and Magazines
28. The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial
29. Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)
30. LBA-007 - FOLFOX/Bevacizumab +/− Irinotecan in advanced colorectal cancer (AIO) “CHARTA”: Final results and multivariate prognostic factor analysis
31. Autorinnen und Autoren
32. Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial
33. Bendamustine Plus Rituximab (B-R) Versus CHOP Plus Rituximab (CHOP-R) As First-Line Treatment in Patients with Indolent and Mantle Cell Lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study
34. Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214)
35. Autorinnen und Autoren
36. Expression of Phospholipse C Gamma 2 in Diffuse Large B-Cell Lymphomas,
37. Patents and profit rates
38. Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)
39. Evaluation of Clinical Judgement at Initiation of AML-Therapy in Elderly Patients - A Prospective Randomized Trial.
40. Progress in solids analysis by sputtered neutral mass spectrometry
41. Differential expression of insulin-like growth factor binding proteins in human non-small cell lung cancer cell lines
42. B-cell lymphoma of the mucosa-associated lymphatic tissue (MALT) presenting with bone marrow and peripheral blood involvement
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.